Gasotransmitter synthesis and signalling in the renal glomerulus. Implications for glomerular diseases.


Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
01 2021
Historique:
received: 08 10 2020
revised: 28 10 2020
accepted: 29 10 2020
pubmed: 6 11 2020
medline: 15 12 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

Glomerular injury is a hallmark of kidney diseases such as diabetic nephropathy, IgA nephropathy or other forms of glomerulonephritis. Glomerular endothelial cells, mesangial cells, glomerular epithelial cells (podocytes) and, in an inflammatory context, infiltrating immune cells crosstalk to mediate signalling processes in the glomerulus. Under physiological conditions, mesangial cells act by the control of extracellular matrix production and degradation, by the synthesis of growth factors and by preserving a well-defined crosstalk with glomerular podocytes and endothelial cells to regulate glomerular structure and function. It is well known that mesangial cells are able to amplify an inflammatory process by the formation of cytokines, reactive oxygen species (ROS) and nitric oxide (NO). This exaggerated reaction may result in a vicious cycle with subsequent damage of neighboured podocytes and endothelial cells, loss of the filtration barrier and, finally destruction of the whole glomerulus. Unfortunately, all efforts to develop new therapies for the treatment of glomerular diseases by controlling unbridled ROS or NO production directly had so far no success. However, on-going research on ROS and NO defined these autacoids more as important signalling molecules than as endogenously produced cytotoxic compounds. New findings on signalling activities of ROS, NO but also hydrogen sulfide (H

Identifiants

pubmed: 33152441
pii: S0898-6568(20)30300-4
doi: 10.1016/j.cellsig.2020.109823
pii:
doi:

Substances chimiques

Cytokines 0
Gasotransmitters 0
Reactive Oxygen Species 0
Nitric Oxide Synthase Type II EC 1.14.13.39
Heme Oxygenase-1 EC 1.14.14.18
Cystathionine gamma-Lyase EC 4.4.1.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

109823

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Karl-Friedrich Beck (KF)

pharmazentrum frankfurt/ZAFES, Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Germany. Electronic address: k.f.beck@em.uni-frankfurt.de.

Josef Pfeilschifter (J)

pharmazentrum frankfurt/ZAFES, Universitätsklinikum Frankfurt, Goethe-Universität, Frankfurt am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH